Clinical UM Guideline

This document addresses limited multiplex respiratory virus testing for individuals in the outpatient setting using either (1) a molecular assay; or (2) an antigen assay, when the test only includes a combination of the following: influenza A, influenza B, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or respiratory syncytial virus (RSV).

Note: Please see the following for use of other respiratory virus panel tests in the outpatient setting:

• CG-LAB-14 Respiratory Viral Panel Testing in the Outpatient Setting.

Note: Single-target assays are not addressed by this document.

Note: Please see the following related document for additional information:

• ADMIN.00007 Immunizations

Note: For a high-level overview of this document, please see "Summary for Members and Families" below.

Medically Necessary:

1. Multiplex molecular respiratory virus testing in the outpatient setting, when the test only includes a combination of the following: influenza A, influenza B, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or respiratory syncytial virus (RSV), is considered medically necessary when all of the following criteria are met:
    
   1. Individual has signs or symptoms of acute respiratory tract infection; and
   2. The test result will guide management, as demonstrated by one or more of the following:
      1. Initiation, continuation, or discontinuation of antiviral therapy; or
      2. Isolation, cohorting, or other infection-prevention measures for the tested individual in a healthcare, long-term care, congregate living, or other high-risk care setting; or
      3. Viral testing is intended to guide antibacterial therapy decisions, and the medical record documents how the result is expected to affect antibacterial therapy through an antimicrobial stewardship or clinical management plan; and isolated bacterial infection is not strongly suspected or has been reasonably evaluated (for example, suspected viral coinfection or diagnostic uncertainty about the causative pathogen).
          
2. Viral antigen testing in the outpatient setting, when the test only includes a combination of the following: influenza A, influenza B, SARS-CoV-2, or RSV, is considered medically necessary when all of the following criteria are met:
    
   1. Rapid molecular testing is not available within the time needed to guide the current clinical encounter or care episode, or the expected turnaround time makes molecular testing impractical for immediate management; and
   2. Individual has signs or symptoms of acute respiratory tract infection; and
   3. The result will guide treatment, antibacterial therapy decisions, or infection-prevention management.

Not Medically Necessary:

Multiplex molecular respiratory virus testing in the outpatient setting, when the test only includes a combination of the following: influenza A, influenza B, SARS-CoV-2, or RSV, is considered not medically necessary when the criteria above have not been met.

Viral antigen testing in the outpatient setting, when evaluation only includes a combination of the following: influenza A, influenza B, SARS-CoV-2, or RSV, is considered not medically necessary when the criteria above have not been met.

This document describes clinical studies and expert recommendations, and explains whether multiplex respiratory virus testing for influenza A, influenza B, SARS-CoV-2 (COVID-19), and respiratory syncytial virus (RSV) is clinically appropriate. The following summary does not replace the medical necessity criteria or other information in this document. The summary may not contain all of the relevant criteria or information. This summary is not medical advice. Please check with your healthcare provider for any advice about your health.

Key Information

Multiplex respiratory virus testing checks for more than one virus or viral target from a single sample, such as a nose or throat swab. This document addresses molecular assays that identify the presence of influenza A, influenza B, and SARS-CoV-2, with or without RSV, and antigen assays that identify proteins the body produces in response to the presence of influenza A, influenza B, and SARS-CoV-2. It does not address single-target assays or other target configurations. Some broader tests can also look for additional respiratory viruses; those tests are addressed in CG-LAB-14. Because many respiratory viruses cause similar symptoms, testing can help healthcare providers decide on antiviral treatment, antibacterial therapy, or infection-prevention measures for the tested individual. Molecular tests detect viral genetic material and are generally more accurate than antigen tests, which detect viral proteins. However, antigen tests may be useful when fast molecular testing is not available and a positive result can guide immediate care. Like any test, results should be understood along with symptoms and other information about the individual.

What the Studies Show

Studies show that molecular respiratory virus tests are generally very accurate for detecting influenza, SARS-CoV-2, RSV, and some other respiratory viruses. Research found that these tests can provide results quickly and may help healthcare providers make decisions about antiviral treatment, antibacterial therapy, infection-control measures, and outbreak response. Hospital trials found that testing provided faster or more actionable diagnoses and improved antiviral or isolation measures. However, not all studies found that such testing resulted in less antibiotic prescribing. One primary-care trial did not reduce same-day antibiotic prescribing overall.

Research found that antigen tests can provide rapid positive results but are usually less accurate than molecular tests, especially when test results are negative. A negative antigen test may miss an infection in some situations. Pediatric emergency department research found frequent positive broad-panel results but that they resulted in only limited change in the care patients received. Additional test results from panels that look for a large number of viruses may not change care when a smaller test panel with fewer viral targets would provide the information needed. Testing that is not tied to a care decision may not provide additional benefit.

When is Multiplex Respiratory Virus Testing Clinically Appropriate?

Only the following limited multiplex configurations are addressed in this document: molecular testing for influenza A, influenza B, and SARS-CoV-2, with or without RSV; and antigen testing for influenza A, influenza B, and SARS-CoV-2. An applicable test may be appropriate when all of these are true:

• The person has signs or symptoms of an acute respiratory tract infection; and
• The result will be available quickly enough to affect the current illness, care visit, or outbreak response; and
• There is a specific care reason for testing, such as deciding about antiviral treatment, antibacterial therapy, isolation or grouping people with similar infections, or infection-control steps.

For lower-risk people treated outside the hospital, influenza testing to decide about antiviral treatment is usually most useful when symptoms started within 48 hours. This timing limit does not apply in the same way to people who are hospitalized, at high risk, or getting worse, because testing may still affect care.

Testing may also be appropriate for symptomatic people at higher risk for severe respiratory viral illness, such as people who are immunocompromised, have chronic heart or lung disease, are pregnant, are very young, are older adults, or have another documented high-risk condition, when the result will guide care.

A broader respiratory virus panel may be appropriate when:

• One of the limited molecular test configurations addressed in this document does not answer the clinical question; and
• Additional respiratory viral results would change care, such as treatment, further evaluation, isolation, grouping people with similar infections, care-location decisions, or outbreak management.

If one of the limited molecular test configurations addressed in this document is negative, follow-up testing, also called ‘reflex testing’, with a broader panel from the same sample may be appropriate only when the person still meets the broader-panel criteria and the added results would change care.

Combined antigen testing for influenza A, influenza B, and SARS-CoV-2 may be appropriate when:

• Rapid molecular testing is not available or practical; and
• The person has symptoms; and
• The result will guide immediate treatment, infection-control measures, or care decisions.

A negative antigen test may need confirmation with a molecular test when suspicion for infection remains high or when a missed infection could affect treatment, infection-control, or care-location decisions. In hospitalized, high-risk, or other high-consequence situations, antigen testing should not be used by itself to rule out infection when molecular testing is needed.

When is this not Clinically Appropriate?

Multiplex respiratory virus testing is not clinically appropriate when the situations listed above are not met. Screening people without signs or symptoms, including pre-procedural screening, admission screening, routine surveillance, or outbreak/protocol-based screening, is not clinically appropriate.

Additionally, repeat testing during the same illness is not clinically appropriate when a previous result is already available and a new result is not expected to change care. Repeat testing may be appropriate when there is a meaningful change in the person's condition, concern that the first sample was poor or falsely negative, there is a suspected second infection or prolonged outbreak, or a treatment or infection-control decision for a high-risk person or setting that would change based on the result.

Broad respiratory virus panels are not clinically appropriate when one of the limited molecular test configurations addressed in this document would answer the clinical question and additional respiratory viral results are not expected to change care. This includes routine broad-panel testing for uncomplicated bronchiolitis or mild upper respiratory tract infection when care would remain supportive and no treatment, infection-control, care-location, or outbreak-management decision would change.

(Return to Description)

The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services may be Medically Necessary when criteria are met:

When services are Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met.

Summary

Acute respiratory tract infections often present with overlapping symptoms, while treatment and infection-prevention decisions may depend on the specific pathogen identified. The evidence does not support multiplex testing for every respiratory illness, but supports timely testing in the outpatient setting when the result is expected to change antiviral treatment, antibacterial therapy decisions, or isolation or cohorting for the tested individual.

For the limited multiplex configurations within this document's scope, the literature most strongly supports molecular testing in symptomatic individuals when results are rapid enough to guide a defined clinical action. It does not support testing of asymptomatic individuals, including pre-procedural screening, admission screening, routine surveillance, or outbreak/protocol-based screening. Broader respiratory virus panels (6 or more targets) are addressed in a separate document.

Discussion

Influenza, coronavirus disease 2019 (COVID-19), respiratory syncytial virus (RSV), and other respiratory viruses can cause similar upper and lower respiratory tract symptoms, but the consequences of identifying a specific virus differ by setting and individual risk. Influenza and COVID-19 have pathogen-specific treatment implications; RSV and other viruses may affect isolation and cohorting decisions for the individual tested (Berry, 2024; Charlton, 2019; Hanson, 2020). This clinical variability supports requiring symptoms plus an expected management impact rather than testing based on symptoms alone.

Signs and symptoms of acute respiratory tract infections (ARIs) vary by whether the upper or lower respiratory tract is involved, and by the specific pathogen, but share a core set of overlapping features, including cough, nasal congestion/discharge, sore throat, and sneezing, often accompanied by malaise and headache.

For influenza, the U.S. Food and Drug Administration (FDA) has approved four antiviral agents with activity against both influenza A and B that differ chiefly in route of administration, treatment course, eligible age range, and mechanism of action (FDA, 1999b, 1999a, 2014, 2018). Oseltamivir, marketed as Tamiflu^®, is an oral neuraminidase inhibitor taken twice daily for 5 days and remains the most broadly applicable option, with approved use for treatment beginning in early infancy and for prophylaxis across most older age groups (FDA, 1999b). Zanamivir, marketed as Relenza, is an orally inhaled neuraminidase inhibitor approved for individuals 7 years of age and older, but it is not recommended for individuals with asthma or chronic obstructive pulmonary disease because of the risk of bronchospasm (FDA, 1999a). Peramivir, marketed as Rapivab^®, is given as a single intravenous infusion for acute uncomplicated influenza in patients at least 6 months of age who have been symptomatic for no more than 2 days, and its efficacy in hospitalized or severe influenza has not been established (FDA, 2014). Baloxavir marboxil, marketed as Xofluza^®, is taken as a single oral dose and is the only agent in this group with a distinct mechanism, inhibiting a cap-dependent endonuclease rather than neuraminidase; it is approved for treatment in patients 5 years of age and older and, separately, for post-exposure prophylaxis (FDA, 2018, 2020b). Across these agents, approved labeling directs that treatment begin within roughly 48 hours of symptom onset (within 2 days for peramivir), reflecting the narrow window in which antiviral therapy provides measurable benefit (FDA, 1999b, 1999a, 2014, 2018).

For COVID-19, the available direct-acting antiviral treatments are directed primarily at patients at high risk of progression to severe disease and differ in route, regimen, and regulatory status (FDA, 2020a, 2021, 2023a). Nirmatrelvir co-packaged with ritonavir, marketed as Paxlovid™, is a fully approved oral 5-day regimen for high-risk adults that reduced the risk of COVID-19-related hospitalization or death by approximately 86% when started within 5 days of symptom onset in the trial supporting approval, and because the ritonavir component strongly inhibits CYP3A, prescribers must screen for drug-drug interactions and reduce the dose in moderate renal impairment (FDA, 2023a). Remdesivir, marketed as Veklury^®, was the first fully approved COVID-19 treatment and is administered intravenously, typically as a 3-day course for outpatients, which requires access to an infusion setting (FDA, 2020a). Its approved labeling spans a broad age range, from term neonates weighing at least 1.5 kg through adults (FDA, 2024). Molnupiravir, marketed as Lagevrio™, is an oral 5-day regimen that is not fully approved, but remains available under emergency use authorization for high-risk adults only when approved or otherwise appropriate options are not accessible, and it is not authorized for individuals younger than 18 years or recommended during pregnancy (FDA, 2021). Most recently, ensitrelvir, marketed as Xocova^®, was approved as an oral option for post-exposure prophylaxis of COVID-19 in adolescents and adults 12 years of age and older, which distinguishes it from the treatment agents above (FDA, 2026). As with the influenza drugs, approved labeling for the oral COVID-19 treatments specifies starting therapy within 5 days of symptom onset, with a somewhat longer window for outpatient remdesivir (FDA, 2020a, 2021, 2023a).

In contrast to influenza and COVID-19, approved antiviral treatment for RSV is markedly limited (FDA, 1985). Aerosolized ribavirin, marketed as Virazole^®, is the only antiviral the agency has approved for RSV, and its use is confined to hospitalized infants and young children with severe lower respiratory tract infection; its delivery is logistically demanding, its benefit is modest, and it carries a teratogenic hazard (FDA, 1985). Because therapeutic options are so constrained, the approved tools for reducing RSV burden are largely preventive rather than therapeutic, consisting of long-acting monoclonal antibodies given as immunoprophylaxis (FDA, 1998, 2023b, 2025). Nirsevimab, marketed as Beyfortus^®, is a single-dose monoclonal antibody approved to prevent RSV lower respiratory tract disease in neonates and infants entering their first RSV season and in certain children up to 24 months of age (FDA, 2023b). Clesrovimab, marketed as Enflonsia™, is a more recently approved single-dose monoclonal antibody for prevention of RSV lower respiratory tract disease in infants entering their first RSV season (FDA, 2025). Palivizumab, marketed as Synagis^®, is an earlier monoclonal antibody that requires monthly dosing through the RSV season and remains approved to prevent serious RSV disease in high-risk infants and young children (FDA, 1998).

Government and Society Guidance

Government and society guidance consistently frames respiratory virus testing as a diagnostic-stewardship decision. Guidance from the Centers for Disease Control and Prevention (CDC) supports testing strategies during co-circulation of influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and RSV when results guide antiviral treatment, COVID-19 management, infection-control measures, or clinical decision-making. Infectious Diseases Society of America (IDSA) guidance describes nucleic acid amplification tests as highly sensitive and specific methods for acute respiratory tract infections, but emphasizes selection based on clinical judgment, pretest probability, and the decision the result is expected to inform (Hanson, 2020; Hayden, 2024a; Hayden, 2024b; Uyeki, 2019).

Professional laboratory guidance supports the same approach. American Society for Microbiology (ASM), Association for Diagnostics and Laboratory Medicine (ADLM), IDSA/ASM laboratory-utilization guidance, and multiplex-panel guidance emphasize that tests differ by target breadth, regulatory status, turnaround time, analytic performance, and interpretation needs, and that test selection should match the clinical question rather than defaulting to the broadest available panel (Berry, 2024; Charlton, 2019; Lewinski, 2023; Miller, 2024). Population-specific guidance also supports restraint: the American Academy of Pediatrics (AAP) discourages routine viral testing in typical bronchiolitis when management is supportive, while American Thoracic Society (ATS), IDSA, and Society for Healthcare Epidemiology of America (SHEA) guidance support testing when results influence treatment or infection prevention (Metlay, 2019; Ralston, 2014; Talbot, 2023; Thampi, 2024).

Diagnostic Stewardship and Workflow

The central clinical-utility theme across randomized trials, health technology assessments, and implementation studies is that testing alone does not reliably improve outcomes; testing is most useful when the result is timely, interpretable, and connected to a pathway for action. Hospital studies provide mechanistic evidence that rapid molecular testing can improve influenza diagnosis, antiviral use, isolation workflows, and care efficiency when results are available during the care episode. However, outpatient and emergency-department evidence shows mixed effects on antibacterial prescribing. Therefore, antibacterial decision-making is supported only when viral testing is tied to a documented stewardship or clinical management pathway, not when testing is untargeted or unlikely to change care (Clark, 2021; Clark, 2023; Hay, 2026; Schober, 2024).

Broader evidence confirms that downstream benefit depends on setting and implementation. A hospital-focused rapid multiplex polymerase chain reaction (PCR) review of 27 studies and 17,321 encounters reported a 24.22-hour reduction in time to result, a 0.82-day reduction in hospital length of stay, increased antiviral use among influenza-positive individuals (Relative Risk [RR], 1.25; 95% confidence interval [CI], 1.06-1.48), and increased appropriate infection-control facility use (RR, 1.55; 95% CI, 1.16-2.07) (Clark, 2023). By contrast, emergency-department and broader rapid-testing reviews found mixed effects on antibiotic use, ancillary testing, length of stay, return visits, and hospitalization; Schober and colleagues found no overall antibiotic-use reduction with rapid respiratory virus testing (RR, 0.99; 95% CI, 0.93-1.05), and subgroup findings did not show a reduction for molecular or multiplex testing (Schober, 2024). A separate systematic review by Mojebi and colleagues, by contrast, reported that rapid molecular testing reduced unnecessary antibiotic and antiviral use, hospital admission, and length of stay (Mojebi, 2024). Long-term care evidence supports staff-initiated testing as part of an outbreak-response workflow, with Temte and colleagues reporting 22% fewer emergency department visits, 21% fewer hospitalizations, and 36% shorter hospital length of stay over 3 influenza seasons. A primary-care randomized trial of rapid respiratory microbiological point-of-care testing in 552 individuals did not reduce same-day antibiotic prescribing overall, although prescribing was lower when a virus was detected (Odds Ratio [OR], 0.35; 95% CI, 0.20-0.63) (Hay, 2026; Temte, 2023). In a pediatric outpatient randomized trial, Li and colleagues found that adding multiplex respiratory PCR to routine care reduced day-of-visit antibiotic prescribing from 66.2% to 55.2% (RR, 0.83; 95% CI, 0.75-0.92), with the reduction concentrated in upper respiratory infections and in WHO “Watch” antibiotics and no difference in time to fever resolution, hospitalization, or 30-day outcomes; even among children who tested positive for influenza, 32.1% still received antibiotics, leading the authors to conclude that point-of-care testing alone is insufficient without accompanying stewardship (Li, 2025). These findings support requiring a planned action rather than treating rapid testing as inherently medically necessary.

Molecular and Antigen Test Performance

Diagnostic accuracy evidence supports molecular testing as the preferred method when an accurate negative result is important. Rapid molecular tests have high diagnostic performance; Vos and colleagues reported pooled sensitivity of 90.9% and specificity of 96.1%, Webster and colleagues found high influenza nucleic acid amplification test (NAAT) accuracy in a review of reviews, Jullien and colleagues reported multiplex molecular sensitivity of 99% for RSV, 97% for influenza A, and 98% for influenza B with specificity of 100% for each target, and Chang and colleagues reported pooled sensitivity of 100.0% and specificity of 99.7% for the Roche cobas^® Liat SARS-CoV-2 and influenza A and B assay, although that source did not address RSV performance (Chang, 2024; Jullien, 2022; Vos, 2019; Webster, 2024). Reviews of Clinical Laboratory Improvement Amendments (CLIA)-waived multiplex point-of-care tests similarly identify multiple available platforms, but device choice and clinical usefulness remain dependent on setting, workflow, and intended use (Bernknopf, 2024).

Rapid antigen tests can provide actionable positive results in symptomatic individuals, but their sensitivity is lower and more variable than molecular testing, especially when viral burden is low or illness timing is less favorable. Rapid-test reviews and recent antigen studies support caution with negative results. Cochrane reviews reported average SARS-CoV-2 antigen sensitivity of 73.0% in symptomatic testing (2022) and 55.0% in asymptomatic testing (2025), despite high specificity of 99.1% and 99.5%, respectively. Bruning and colleagues reported pooled rapid-test sensitivity of 61.1% for influenza and 75.3% for RSV, while Meyer and colleagues found that combined antigen-test performance declined at cycle threshold values above 25. Cohen and colleagues reported pediatric ambulatory triple-test sensitivities of 93.7% for influenza A, 96.0% for influenza B, 85.9% for RSV, and 71.4% for SARS-CoV-2; the SARS-CoV-2 estimate was imprecise because SARS-CoV-2 incidence was very low during the study period, and specificity was 100% for each target (Bruning, 2017; Cohen, 2026; Dinnes, 2022; Dinnes, 2025; Meyer, 2025; Savolainen, 2025). A systematic review and meta-analysis by Gentilotti and colleagues of point-of-care tests for acute community-acquired lower respiratory tract infections (which did not include SARS-CoV-2), spanning primary care, outpatient clinic, emergency department, and long-term care settings, found that molecular tests outperformed rapid tests for every pathogen studied, while rapid antigen tests for influenza, RSV, human metapneumovirus, and Streptococcus pneumoniae had sub-optimal sensitivity (range 49%-84%) despite high specificity (> 80%). The authors cautioned that antigen tests cannot be considered fully reliable because of high false-negative rates (Gentilotti, 2022). These findings support antigen testing as an alternative for actionable positive results when rapid molecular testing is not available within the time needed to guide immediate management, with molecular confirmation considered when a missed infection would affect treatment or infection prevention. The Canadian Agency for Drugs and Technologies in Health (CADTH) similarly noted that point-of-care tests may speed diagnosis, while laboratory-based NAAT remains the standard for diagnostic performance and confirmatory testing.

Limited Multiplex Testing

The evidence supports limited molecular assays that detect influenza A, influenza B, and SARS-CoV-2, with or without RSV, as the core multiplex use because these pathogens commonly co-circulate and have relatively direct treatment or infection-prevention implications. The antigen configuration addressed in this document detects influenza A, influenza B, and SARS-CoV-2. The evidence does not show that adding non-core viral targets routinely improves management when one of these limited assays answers the clinical presentation. This distinction supports using an applicable limited assay as the default when it answers the clinical presentation, not for routine testing of all symptomatic individuals.

Broad-panel restraint is especially important because diagnostic accuracy does not by itself establish clinical utility. Multiplex respiratory pathogen panels can identify additional viruses, but professional guidance emphasizes choosing panel breadth based on the clinical context. In Goodfellow and colleagues' pediatric emergency department study, 71.3% of 2052 respiratory pathogen panels were positive, but management changed in only 5.5% of infants and 3% of young children; retrospective stewardship criteria suggested that unnecessary panel testing could be reduced by 48%, with anticipated cost savings and without significant impact on patient management (Goodfellow, 2026; Miller, 2024). Broader respiratory virus panels (6 or more targets) are outside the scope of this document and are addressed in CG-LAB-14.

Pediatric Evidence and Broad Application

Pediatric evidence does not require separate pediatric criteria; it reinforces that testing should be tied to an action. The AAP bronchiolitis guideline discourages routine viral testing when management is supportive, and Goodfellow and colleagues found limited real-time management impact from broad pediatric emergency department panels despite a high positivity rate (Goodfellow, 2026; Ralston, 2014). Low-yield pediatric testing is therefore not supported when the result is not expected to change antiviral treatment, antibacterial therapy decisions, or isolation.

At the same time, pediatric data support testing when results are embedded in a defined workflow or needed for epidemiologic interpretation. Molecular testing integrated with antimicrobial and diagnostic stewardship in Reyes-Chacón and colleagues' hospitalized pediatric study was associated with lower antibiotic prescribing on day 1 (34.5% vs. 81.0%) and day 3 (29.0% vs. 53.0%) and shorter median length of stay (5 vs. 6 days), while Toepfer and Teoh provide context that clinical testing patterns and viral detections shape interpretation of pediatric disease burden (Reyes-Chacón, 2026; Teoh, 2025; Toepfer, 2025). Together, pediatric and adult evidence support broad age applicability, while the management-impact requirement naturally filters out settings where viral identification is unlikely to change care.

Coinfection and Co-Circulation

Co-circulation and coinfection evidence supports combined testing when results will influence management, while also supporting restraint when additional results are not actionable. Swets and colleagues evaluated 212,466 hospitalized adults with SARS-CoV-2; among 6,965 tested for selected respiratory viral coinfections, 583 had a detected coinfection, and influenza coinfection was associated with worse outcomes while the same pattern was not shown for RSV or adenovirus coinfection in adjusted analyses (Swets, 2022). This evidence supports the limited molecular configuration that includes influenza A, influenza B, SARS-CoV-2, and RSV during co-circulation when results will guide treatment or isolation for the individual tested.

Public health surveillance and outbreak control are distinct from individual diagnostic testing and are not, by themselves, a basis for medical necessity under this document.

Acute respiratory tract infection: An infection involving the upper or lower respiratory tract that may present with symptoms such as cough, fever, sore throat, nasal congestion, rhinorrhea, wheezing, shortness of breath, hypoxia, or worsening of chronic respiratory disease.

Antigen test: A diagnostic test that detects viral proteins. Antigen tests can produce rapid results but generally have lower sensitivity than molecular tests, especially when viral load is low.

Broader respiratory virus panel (large panel): In this document, this term refers to a multiplex respiratory virus test that includes any viral target other than influenza A, influenza B, SARS-CoV-2, and RSV, or that detects 6 or more respiratory viral targets. A limited respiratory virus assay addressed in this document is either (1) a molecular assay that detects influenza A, influenza B, and SARS-CoV-2, with or without RSV; or (2) an antigen assay that detects influenza A, influenza B, and SARS-CoV-2. Single-target assays and all other target configurations are outside the scope of this document. The 6-or-more threshold is consistent with CG-LAB-14, but this document's medical necessity criteria apply only to the configurations specified in Sections I and II. In this document, broader respiratory virus panel does not refer to bacterial or atypical pathogen panels.

Coronavirus disease 2019 (COVID-19): Illness caused by the SARS-CoV-2 virus.

Multiplex respiratory virus test: A test that evaluates a single respiratory specimen for more than one respiratory virus or viral target during the same testing process.

Nucleic acid amplification test: A molecular test that detects genetic material from a pathogen. Polymerase chain reaction testing is one type of nucleic acid amplification test.

Point-of-care test: A test performed near the site of care, with results available during the clinical encounter or soon enough to influence immediate care.

Rapid molecular testing: Molecular testing, including nucleic acid amplification testing, with results available soon enough to affect treatment, antibacterial therapy, or infection-prevention decisions during the relevant clinical encounter or care episode.

Respiratory syncytial virus: A respiratory virus that can cause bronchiolitis, pneumonia, and severe disease in infants, older adults, and individuals with certain medical conditions.

SARS-CoV-2: The virus that causes COVID-19.

Peer Reviewed Publications:

1. Bernknopf AC, Koski RR, Konieczny AM, et al. Multiplex CLIA-waived point-of-care tests for SARS-CoV-2, influenza A and B, with or without other respiratory pathogens: a systematic review. J Am Pharm Assoc (2003). 2024; 64(4):102090.
2. Berry GJ, Jhaveri TA, Larkin PMK, et al. ADLM guidance document on laboratory diagnosis of respiratory viruses. J Appl Lab Med. 2024; 9(3):599-628.
3. Bruning AHL, Leeflang MMG, Vos JMBW, et al. Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis. Clin Infect Dis. 2017; 65(6):1026-1032.
4. Chang E, Jeon K, Lee N, et al. Clinical performance of the Roche Cobas Liat SARS-CoV-2 & influenza A/B assay: a systematic review and meta-analysis. J Clin Virol. 2024; 174:105706.
5. Charlton CL, Babady E, Ginocchio CC, et al. Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections. Clin Microbiol Rev. 2019; 32(1):e00042-18.
6. Clark TW, Beard KR, Brendish NJ, et al. Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(4):419-429.
7. Clark TW, Lindsley K, Wigmosta TB, et al. Rapid multiplex PCR for respiratory viruses reduces time to result and improves clinical care: results of a systematic review and meta-analysis. J Infect. 2023; 86(5):462-475.
8. Cohen R, Batard C, Romain O, et al. Performance of a rapid triple test, SARS-CoV-2 + influenza A/B + respiratory syncytial virus compared with RT-PCR for ambulatory pediatric patients. Pediatr Infect Dis J. 2026; 45(6):543-548.
9. Gentilotti E, De Nardo P, Cremonini E, et al. Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis. Clin Microbiol Infect. 2022; 28(1):13-22.
10. Goodfellow SM, Bard JD, Lee V, et al. Utility of a multiplex molecular respiratory pathogen panel on clinical management of children in the pediatric emergency department. J Mol Diagn. 2026. May 4:S1525-1578(26)00069-3.
11. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA's Diagnostics Committee. Clin Infect Dis. 2020; 71(10):2744-2751.
12. Hay AD, Abbs S, Ridd M, et al. Rapid respiratory microbiological point-of-care testing and antibiotic use in primary care: randomized clinical trial. JAMA Intern Med. 2026. Published online May 18, 2026.
13. Jullien S, Fitzgerald F, Keddie S, et al. Diagnostic accuracy of multiplex respiratory pathogen panels for influenza or respiratory syncytial virus infections: systematic review and meta-analysis. BMC Infect Dis. 2022; 22(1):785.
14. Li YN, Lv J, Zhou J, et al. Impact of point-of-care PCR testing on antibiotic prescribing in pediatric outpatients with acute respiratory infections: a randomized clinical trial. J Infect Public Health. 2025; 18(9):102847.
15. Meyer J, Gosert R, Bingisser R, et al. Diagnostic performance of a combined rapid antigen test for detecting SARS-CoV-2, influenza virus, and respiratory syncytial virus in symptomatic patients in tertiary care. J Med Virol. 2025; 97(7):e70493.
16. Mojebi A, Wu P, Keeping S, et al. Clinical impact of rapid molecular diagnostic tests in patients presenting with viral respiratory symptoms: a systematic literature review. PLoS One. 2024; 19(6):e0303560.
17. Reyes-Chacón J, Romero-Alvarez D, Vanoni SE, et al. Clinical impact of molecular testing for respiratory viruses in children admitted with acute respiratory diseases: real-world evidence. Risk Manag Healthc Policy. 2026; 19:559102.
18. Savolainen LE, Peltola J, Hilla R, et al. Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics. Microbiol Spectr. 2025; 13(1):e0163024.
19. Schober T, Wong K, DeLisle G, et al. Clinical outcomes of rapid respiratory virus testing in emergency departments: a systematic review and meta-analysis. JAMA Intern Med. 2024; 184(5):528-536.
20. Swets MC, Russell CD, Harrison EM, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022; 399(10334):1463-1464.
21. Talbot TR, Hayden MK, et al. Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: challenges and considerations. Infect Control Hosp Epidemiol. 2023; 44(1):2-7.
22. Temte JL, Checovich MM, Barlow S, et al. Rapid detection of influenza outbreaks in long-term care facilities reduces emergency room visits and hospitalization: a randomized trial. J Am Med Dir Assoc. 2023; 24(12):1904-1909.
23. Teoh Z, Toepfer AP, Rohlfs C, et al. Viral detection in children younger than 5 years with bronchiolitis, pneumonia, and croup, New Vaccine Surveillance Network, 2017-2023. J Pediatric Infect Dis Soc. 2025; 14(11):piaf096.
24. Toepfer AP, Rutkowski RE, Sahni LC, et al. Clinical testing for COVID-19, influenza, and RSV in hospitalized youths, 2016-2024. JAMA Netw Open. 2025; 8(9):e2531499.
25. Vos LM, Bruning AHL, Reitsma JB, et al. Rapid molecular tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review of diagnostic accuracy and clinical impact studies. Clin Infect Dis. 2019; 69(7):1243-1253.
26. Webster KE, Parkhouse T, Dawson S, et al. Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews. Health Technol Assess. 2024:1-75.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Association for Diagnostics and Laboratory Medicine. Laboratory diagnosis of respiratory viruses. May 2, 2024. Available at: https://myadlm.org/science-and-research/academy-guidance/laboratory-diagnosis-of-respiratory-viruses. Accessed on August 14, 2026.
2. American Society for Microbiology. Clinical utility of multiplex tests for respiratory and GI pathogens. August 23, 2019. Available at: https://asm.org/guideline/clinical-utility-of-multiplex-tests-for-respirator. Accessed on August 14, 2026.
3. Canadian Agency for Drugs and Technologies in Health. Point-of-care tests for COVID-19 and influenza in Canada. May 2024. NCBI Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK604825/. Accessed on August 14, 2026.
4. Centers for Disease Control and Prevention. Clinical guidance for hospitalized and non-hospitalized patients when SARS-CoV-2, RSV, and influenza viruses are co-circulating. May 4, 2026. Available at: https://www.cdc.gov/flu/hcp/clinical-guidance/testing-guidance-for-clinicians.html. Accessed on August 14, 2026.
5. Centers for Disease Control and Prevention. Diagnostic Testing for RSV. February 24, 2026. Available at: https://www.cdc.gov/rsv/hcp/clinical-overview/diagnostic-testing.html. Accessed on August 14, 2026.
6. Centers for Disease Control and Prevention. Multiplex Tests to Detect Influenza, SARS-CoV-2, and RSV. April 27, 2026. Available at: https://www.cdc.gov/flu/hcp/testing-methods/flu-covid19-detection.html. Accessed on August 14, 2026.
7. Dinnes J, Berhane S, Walsh J, et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2025; 11:CD013705.
8. Dinnes J, Sharma P, Berhane S, et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2022; 7:CD013705.
9. Hayden MK, Hanson KE, Englund JA, et al. The Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing (January 2023). Clin Infect Dis. 2024a; 78(7):e350-e384.
10. Hayden MK, Hanson KE, Englund JA, et al. The Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing (December 2023). Clin Infect Dis. 2024b; 78(7):e385-e415.
11. Infectious Diseases Society of America. COVID-19 guideline part 3: molecular diagnostic testing. September 6, 2023. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/. Accessed on August 14, 2026.
12. Infectious Diseases Society of America. COVID-19 Guideline Part 5: Antigen testing. December 20, 2022. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-antigen-testing/. Accessed on August 14, 2026.
13. Infectious Diseases Society of America. Seasonal influenza guideline. December 19, 2018. Available at: https://www.idsociety.org/practice-guideline/influenza/. Accessed on August 14, 2026.
14. Lewinski MA, Alby K, Babady NE, et al. Exploring the utility of multiplex infectious disease panel testing for diagnosis of infection in different body sites: a joint report of the Association for Molecular Pathology, American Society for Microbiology, Infectious Diseases Society of America, and Pan American Society for Clinical Virology. J Mol Diagn. 2023; 25(12):857-875.
15. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7):e45-e67.
16. Miller JM, Binnicker MJ, Campbell S, et al. Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024. Mar 5:ciae104.
17. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014; 134(5):e1474-e1502.
18. Thampi N, Guzman-Cottrill J, Bartlett AH, et al. SHEA NICU white paper series: practical approaches for the prevention of viral respiratory infections. Infect Control Hosp Epidemiol. 2024; 45(3):267-276.
19. U.S. Food and Drug Administration. Beyfortus (nirsevimab-alip) injection. Drugs@FDA: FDA-Approved Drugs. Approved July 17, 2023. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761328. Accessed on August 14, 2026.
20. U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. News release. December 23, 2021. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain. Accessed on August 14, 2026.
21. U.S. Food and Drug Administration. Enflonsia (clesrovimab-cfor) injection. Drugs@FDA: FDA-Approved Drugs. Approved June 9, 2025. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761432. Accessed on August 14, 2026.
22. U.S. Food and Drug Administration. FDA approves first oral antiviral for treatment of COVID-19 in adults. News release. May 25, 2023. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults. Accessed on August 14, 2026.
23. U.S. Food and Drug Administration. FDA approves first treatment for COVID-19. News release. October 22, 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed on August 14, 2026.
24. U.S. Food and Drug Administration. Novel drug approvals for 2026: Xocova (ensitrelvir), approved May 29, 2026. Updated August 11, 2026. Available at: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026. Accessed on August 14, 2026.
25. U.S. Food and Drug Administration. Rapivab (peramivir) injection. Drugs@FDA: FDA-Approved Drugs. Approved December 19, 2014. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206426. Accessed on August 14, 2026.
26. U.S. Food and Drug Administration. Relenza (zanamivir) inhalation powder. Drugs@FDA: FDA-Approved Drugs. Approved July 26, 1999. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021036. Accessed on August 14, 2026.
27. U.S. Food and Drug Administration. Synagis (palivizumab) injection. Drugs@FDA: FDA-Approved Drugs. Approved June 19, 1998. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103770. Accessed on August 14, 2026.
28. U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) capsules and oral suspension. Drugs@FDA: FDA-Approved Drugs. Approved October 27, 1999. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021087. Accessed on August 14, 2026.
29. U.S. Food and Drug Administration. Veklury (remdesivir) for injection. Drugs@FDA: FDA-Approved Drugs. Pediatric indication extended to term neonates weighing at least 1.5 kg, 2024. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214787. Accessed on August 14, 2026.
30. U.S. Food and Drug Administration. Virazole (ribavirin) for inhalation solution. Drugs@FDA: FDA-Approved Drugs. Approved December 31, 1985. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018859. Accessed on August 14, 2026.
31. U.S. Food and Drug Administration. Xofluza (baloxavir marboxil) tablets. Drugs@FDA: FDA-Approved Drugs. Approved October 24, 2018. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210854. Accessed on August 14, 2026.
32. U.S. Food and Drug Administration. Xofluza (baloxavir marboxil): efficacy-new indication supplement for post-exposure prevention. Drugs@FDA: FDA-Approved Drugs. Approved November 23, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/214410Orig1s000;%20210854Orig1s004,%20s010ltr.pdf. Accessed on August 14, 2026.
33. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019; 68(6):e1-e47.

1. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov. Accessed on August 14, 2026.
2. Infectious Diseases Society of America. Available at: https://www.idsociety.org. Accessed on August 14, 2026.
3. Association for Diagnostics and Laboratory Medicine. Available at: https://myadlm.org. Accessed on August 14, 2026.
4. American Society for Microbiology. Available at: https://asm.org. Accessed on August 14, 2026.

Multiplex Respiratory Virus Testing
Point-of-Care Respiratory Virus Testing
Respiratory Pathogen Panel
SARS-CoV-2, Influenza, and RSV Testing

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.

Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only - American Medical Association